NCT05457868View on ClinicalTrials.gov

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Salbutamol vs Long-acting Muscarinic Antagonists

CompletedOBSERVATIONAL
Enrollment

124,117

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

July 30, 2022

Study Completion Date

December 31, 2023

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Salbutamol

Salbutamol claim is used as the exposure group.

DRUG

LAMA

Long-acting muscarinic antagonists (LAMA) - umeclidinium, aclidinium, tiotropium, glycopyrolate, glycopyrronium - claim is used as the reference group.

Trial Locations (1)

02120

Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

collaborator

Rutgers University

OTHER

collaborator

Johns Hopkins University

OTHER

lead

Brigham and Women's Hospital

OTHER

NCT05457868 - Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Salbutamol vs Long-acting Muscarinic Antagonists | Biotech Hunter | Biotech Hunter